NO20084645L - Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer - Google Patents

Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer

Info

Publication number
NO20084645L
NO20084645L NO20084645A NO20084645A NO20084645L NO 20084645 L NO20084645 L NO 20084645L NO 20084645 A NO20084645 A NO 20084645A NO 20084645 A NO20084645 A NO 20084645A NO 20084645 L NO20084645 L NO 20084645L
Authority
NO
Norway
Prior art keywords
hcv ns5b
ns5b inhibitors
cyclopropyl
condensed
indolobenzazepine
Prior art date
Application number
NO20084645A
Other languages
English (en)
Norwegian (no)
Inventor
Carl P Bergstrom
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20084645L publication Critical patent/NO20084645L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
NO20084645A 2006-05-25 2008-11-04 Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer NO20084645L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80833106P 2006-05-25 2006-05-25
PCT/US2007/069660 WO2007140254A2 (en) 2006-05-25 2007-05-24 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
NO20084645L true NO20084645L (no) 2008-12-19

Family

ID=38617899

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084645A NO20084645L (no) 2006-05-25 2008-11-04 Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer

Country Status (9)

Country Link
US (1) US7456167B2 (de)
EP (1) EP2029606B1 (de)
JP (1) JP5205370B2 (de)
CN (1) CN101490054B (de)
AT (1) ATE469155T1 (de)
DE (1) DE602007006796D1 (de)
ES (1) ES2343914T3 (de)
NO (1) NO20084645L (de)
WO (1) WO2007140254A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2494991A1 (de) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Kombinationstherapie zur Behandlung von HIV-Infektionen
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN101918410B (zh) * 2007-11-20 2013-02-27 百时美施贵宝公司 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CN103483251A (zh) 2007-12-19 2014-01-01 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
CN102046630A (zh) * 2008-03-27 2011-05-04 百时美施贵宝公司 吡咯烷稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
JP2011515486A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の治療用化合物
JP2011515496A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
WO2009120650A1 (en) 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Aromatic heterocyclic fused indolobenzadiazepine hcv ns5b inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376515A1 (de) * 2008-12-23 2011-10-19 Pharmasset, Inc. Synthese von purinnukleosiden
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Sciences, Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3650014B1 (de) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Kombinationsformulierung von zwei antiviralen verbindungen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE428714T1 (de) * 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
DE502005002697D1 (de) 2004-10-13 2008-03-13 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
EP1807397A2 (de) * 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetrazyklische indolderivate als antivirale wirkstoffe
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
CN101490054B (zh) 2012-05-16
US20070275947A1 (en) 2007-11-29
EP2029606B1 (de) 2010-05-26
JP2009538347A (ja) 2009-11-05
ATE469155T1 (de) 2010-06-15
WO2007140254A2 (en) 2007-12-06
CN101490054A (zh) 2009-07-22
JP5205370B2 (ja) 2013-06-05
WO2007140254A3 (en) 2008-01-24
ES2343914T3 (es) 2010-08-12
EP2029606A2 (de) 2009-03-04
US7456167B2 (en) 2008-11-25
DE602007006796D1 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
NO20084645L (no) Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer
NO341663B1 (no) Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer
ATE483712T1 (de) Hcv-ns5b-inhibitoren
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
NO20092053L (no) HCV NS3-proteaseinhibitorer
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
EA201170241A1 (ru) Макроциклические хиноксалиновые соединения в качестве ингибиторов протеазы вгс ns3
NO20070751L (no) Inhibitorer av HCV-replifikasjon
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
TW200720285A (en) Nucleoside compounds for treating viral infections
WO2008051477A3 (en) Hcv ns3 protease inhibitors
NO20091591L (no) Hepatitt C virusinhibitorer
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
WO2006119061A3 (en) Hcv ns3 protease inhibitors
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
WO2007120595A3 (en) Amines for the treatment of hcv
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
UA90909C2 (en) Hcv ns3 protease inhibitors
UA95990C2 (en) Hcv ns3 protease inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application